

New strategic function at Gambro to focus on long term value-added growth

Stockholm, Sweden, November 27, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that a new function, Gambro Strategic Development (GSD), has been established at Gambro. GSD will serve as a "Center of Excellence" for strategic development with the goal to create long term value for the group. Key activities for GSD will be to support Gambro management in managing the overall corporate strategic agenda, to provide business building capabilities and resources to high potential growth initiatives and to manage Gambro's venture portfolio. Annemarie Gardshol, presently Vice President, Strategic Development, Gambro Renal Products, has been appointed Senior Vice President, GSD. In her new role Annemarie Gardshol will be a member of the Gambro Executive Committee and report to Sören Mellstig, President and CEO of Gambro.

Bengt Modéer, presently Senior Vice President, Corporate Communications, Gambro has been appointed Senior Vice President, Innovation Management. Olof Stocksén, presently Director, Corporate Business Development, has been appointed Vice President, Corporate Business Development and Märta Mörling, presently Group Internet and Intranet Manager, Gambro, has been appointed Manager, Knowledge Management. Modéer, Stocksén and Mörling will report to Gardshol.

Gambro also announces that Karin Avasalu, presently Group Internal Communications Manager, Gambro, has been appointed Vice President, Corporate Communications. In her new position Karin Avasalu will report to Sören Mellstig. Investor Relations from now on reports into Corporate Finance. Bengt Modéer will remain responsible for Gambro's Investor Relations.

"The creation of GSD supports our overall corporate strategy to further integrate our three business areas and capitalize on the joint opportunities we see in our present and adjacent markets," says Sören Mellstig, President and CEO of Gambro. "The restructuring of our corporate functions represents a reallocation of resources to a more business driven corporate center design."

The new organization is effective as of December 1, 2000.

For further information please contact:

Bengt Modéer, tel. +46-8-613 65 00, +46-70-513 65 33

Karin Avasalu, tel. +46-8-613 65 00, +46-70-513 65 99

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 47,000 patients in 600 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 18,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com